Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) Operating Expenses (2022 - 2025)

CervoMed's Operating Expenses history spans 9 years, with the latest figure at $8.4 million for Q3 2025.

  • For Q3 2025, Operating Expenses rose 14.05% year-over-year to $8.4 million; the TTM value through Sep 2025 reached $33.4 million, up 41.77%, while the annual FY2024 figure was $28.0 million, 86.96% up from the prior year.
  • Operating Expenses for Q3 2025 was $8.4 million at CervoMed, roughly flat from $8.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $9.4 million in Q4 2024 and bottomed at -$3.3 million in Q4 2022.
  • The 4-year median for Operating Expenses is $4.9 million (2024), against an average of $4.7 million.
  • The largest YoY upside for Operating Expenses was 364.75% in 2023 against a maximum downside of 37.77% in 2023.
  • A 4-year view of Operating Expenses shows it stood at -$3.3 million in 2022, then surged by 250.29% to $5.0 million in 2023, then skyrocketed by 89.15% to $9.4 million in 2024, then decreased by 11.02% to $8.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Operating Expenses are $8.4 million (Q3 2025), $8.4 million (Q2 2025), and $7.2 million (Q1 2025).